Kancera strengthens patent rights related to ROR antibody therapy
Kancera announces that it has signed an agreement with Bioinvent to acquire BioInvent ́s rights to the patent application WO 2011/079902, covering therapeutic antibodies directed against the ROR receptor for treatment of cancer.
Read More